Nemysis Team
Within Nemysis we run a lean Leadership Team with diverse and complementary skill sets with extensive expertise and successful track records in specialty pharma.
We have strong scientific, R&D, medical, pharmaceutical, and commercial know-how to bring products to market. We have a clear aspiration and commitment to utilise cutting edge science and technology to address unmet clinical needs. Within the team, we have solid experience of starting up, developing, growing, and divesting specialty pharma companies.
The Leadership Team is supported by our highly respected scientific advisory board who provide specialist support. It is composed of a strong network of scientists and clinicians from academic and health institutions across the EU, and who are renowned experts in their field.
Founder and CEO, Danilo has extensive experience as a senior pharmaceutical executive and as an entrepreneur. He was President and CEO of Fidia Pharmaceuticals, USA, and Director of International Corporate Development with Fidia Farmaceutici S.p.A. He also served as VP, Corporate Development at Madaus AG and held several senior management positions in several Pharma Companies. As a serial entrepreneur he has founded several pharmaceutical companies, including, CM&D Pharma Limited, a company focused on prescription Medical Foods, which was acquired by Nestle Health Science in 2011.
A passionate researcher into the relationship between epigenetics and nutrition. Her focus is the role that specific nutrients could exert in primary, and particularly in secondary, prevention of chronic diseases as functional adjuncts to medicinal products. Cristina has held senior R&D management positions in a number of European companies, is an inventor on numerous patents and often consults on regulatory affairs. She served as director in CM&D Pharma, acquired by Nestle Health Science. Cristina is a Member of the Board in ExPharma Limited, a UK based R&D Company.
Marco Cartolari is an entrepreneur with over 25 years of managerial and entrepreneurial experience in a range of industries, including healthcare and financial services. Ex-CEO of a pharmaceutical company in Europe, Marco currently advises, invests in and serves on the board of a variety of start-up businesses. Marco has an MBA in Marketing and Finance from Columbia University and a BA (Laurea) in Business Administration from Bocconi University, Milan.
Max has significant financial leadership experience delivering business growth, scale-up, optimisation and corporate transactions. Max joined the audit practice of Smith and Williamson, gaining broad industry experience, before joining Deloitte LLP (London) in 2007 where, as Director, Corporate Finance, he supported domestic and international clients achieve value accretive growth through transformational mergers, acquisitions and disposals, as well as fundraising and capital market transactions. Max now applies his expertise to driving growth of owner-led, entrepreneurial businesses.
Max is a graduate of Imperial College of Science, Technology and Medicine (BSc) and a certified Chartered Accountant (ACA).
Katharina is a nutritional scientist whose research aims to understand how dietary, medicinal and lifestyle interventions can modulate human health. Prior to joining Nemysis Ltd, she did her postdoc at the University of Cambridge, where she worked with the inventors of ‘IHAT’, Nemysis’ novel oral iron supplement, investigating physico-chemical, in vitro and in vivo properties. Katharina holds a BSc in Nutritional Science from the Technical University Munich (TUM) and a PhD in Medical Science from Charité, Berlin.
Antonino is a Chemist with over 30 years of experience in Regulatory Affair in Healthcare Industry with a strong expertise in the development of prescription and nutraceutical products. He served for several yerars in Rottapharm/Madaus - an R&D pharmaceutical company with commercial activities and diversified presence into the market with Medicinal Products, Food Supplements, Medical Devices and Cosmetics - where he was responsible for Regulatory Affairs and Business Development at the corporate level and secured regulatory authorization of hundreds of products in over 60 countries. Currently he is a senior advisor for pharma and nutraceutical companies. He is a board member of Federsalus (Italian Association of Food Supplements) since 2005. In 2013 he was elected Vice-President of Federsalus, with the mandate to represent the Association in front of the European Institution and liaise with other European Associations and, as such, was elected in the board of EHPM, the European Federation of Associations of Health Product Manufacturers.
Nuno is currently the Chief Tecnical Officer in Nemysis Ltd. Previously Scientific Officer at NoBACZ Healthcare Ltd, he worked also with Professor Powel at the Bio-Mineral Research at the MRC’s Human Nutrition Research (‘‘HNR’’) Elsie Widdowson Laboratory in Cambridge, where his work focused on the absorption of iron and diagnosis and treatment of iron deficiency; the role of minerals, in inflammatory and anti-inflammatory processes of the gastrointestinal tract and the development of novel mineral-based therapeutics. Dr Faria contributed to invention of the patented technology behind IHAT which Nemysis Ltd acquired the licence from the MRC in late 2017.
A highly experienced lawyer with many years’ experience of the life sciences industry. A Barrister for 2 years, Legal Adviser and subsequently Manager, Legal Affairs at Smith Kline UK for 4 years. Director, Legal Affairs at Merck Sharp & Dohme UK for 5 years. Associate and subsequently Head of Life Sciences at Simmons & Simmons (UK law firm) for 11 years. Partner and Head of International Life Sciences at Fasken Martineau (Anglo-Canadian law firm) for 12 years. Partner, Life Sciences, Pinsent Masons (solicitors) for 2 years. In private practice core clients over the years have included big pharma/medtech (e.g. Novartis, AZ, Merck US and Merck Serono, Lilly, Novo, Boehringer, UCB, Becton Dickinson, Smith & Nephew, Teva, Allergan.
A Chemist with over 30 years’ experience in Healthcare Industry, in Pharmaceuticals and Nutraceuticals. He is one of the founders and Managing Director of Gencor group worldwide. He has extensive experience in International Business in the Pharmaceutical and Nutraceutical sectors worldwide, having conducted business in over 70 countries. He has extensive experience in R&D Management, scientific reviews, product development, clinical trials, branding, strategic partnerships and has a track record of successful branded product launches worldwide in the nutraceutical segment.
Guru is a Senior Executive specialising in Global Healthcare innovation management and commercialisation. He served as Chief Innovation Officer at General Nutrition Corporation and, before that, he was Sr. Director of Scientific Affairs at Royal Numico (now Nutricia-Danone). Guru has MBA in general management with special emphasis on global business practices, and a Ph.D in healthcare innovation management, focused upon customer centric R&D, strategic business planning and pre & post marketing activities. A clinician by discipline, Guru specialised in cranio-facial growth & development, with 35 years of clinical and research experience both within and outside the US.
Howard is CEO of Ajinomoto Cambrooke, Inc., a fast-growing leader in Medical Nutrition for people with chronic health conditions. He previously held numerous medical nutrition leadership positions with Nutricia (a subsidiary of Danone) guiding business strategy, development and acquisitions during his tenure based in the US, Canada and the United Kingdom. Howard was previously an executive in two successful start-up technology firms and with Procter & Gamble (P&G) in several brand management positions in P&G’s Health Care and Paper divisions.
Antonio Maggi is a manager with over 30 years of managerial and entrepreneurial experience in a range of industries, including healthcare and petroleum. Ex-CEO and Managing Director of a pharmaceutical company in Italy, Antonio has also gained broad experience in pharmaceutical marketing and sales networks management. Currently he works with the board of a variety of start-up businesses. Antonio has a Master’s Degree in Economics from Politecnico delle Marche University of Ancona.
Alia is a Director and Co-founder of The Life Sciences Division, a UK based, FCA regulated Investment bank serving the global life sciences industry. She has previously established private equity and offshore funds and co-created a number of life sciences private equity backed businesses. Executing on fundraising, mergers, acquisitions and divestments. Alia worked as a buy side equity analyst and Associate Director in the biotech sector at Mulier Capital, an Investment bank and Investment management firm that specialised in gene therapies. Prior to this, Alia’s formative banking career was at Lloyds Banking Group and Scottish Widows Investment Partnership.
Scientific Director at Ulysse-Consult Sarl
Margit Holzer is a passionate biochemical engineer with internationally recognized expertise in development, industrialization and implementation of biotechnological production processes, in the field of pharma and food applications. She holds a master and a PhD in biotechnology from the University of Natural Resources and Applied Life Sciences in Vienna (Austria). Margit has worked all over Europe for Boehringer-Ingelheim and Novasep, she headed various positions in R&D, production, quality, technology and business including several worldwide executive ones. Since end of 2012 she serves the industry as an independent consultant at Ulysse-Consult. Amongst other achievements she has supervised product and process development of more than 60 different products, several of them reached market authorization.
Head of Bio-Mineral Research at University of Cambridge
Professor Jonathan Powell is Head of Bio-Mineral Research at Cambridge University, where he and his team work with trace elements and mineral structures, especially nanoparticles, trying to identify their benefit to health as part of normal physiology. Prior to his current position, he was Head of Bio-mineral Research at the MRC’s Human Nutrition Research (‘‘HNR’’) Elsie Widdowson Laboratory in Cambridge. Within HNR, his work focused on the absorption of iron and diagnosis and treatment of iron deficiency; the role of minerals in inflammatory and anti-inflammatory processes of the gastrointestinal tract and the development of novel mineral-based therapeutics. Prof Powell and his team were the inventors of the patented technology behind IHAT which Nemysis Ltd acquired the licence from the MRC in late 2017.
Professor of Gastroenterology and Consultant Gastroenterologist at the Royal Hallamshire Hospital & the University of Sheffield, United Kingdom
David S Sanders is a Professor of Gastroenterology and a Consultant Gastroenterologist at the Royal Hallamshire Hospital & the University of Sheffield, UK. He has over 400 peer reviewed papers. Internationally recognised for his work in celiac disease and gluten related disorders. Recipient of research awards: European Rising Star Award, Cuthbertson Medal (and Silver Medal (the latter two awards from the UK Nutrition Society), Swedish Gastroenterology Society Bengt Ihre Medal and most recently the British Society for Gastroenterology (BSG) Hopkins prize for Endoscopy . Coeliac UK Healthcare Professional of the Year Award (2010. He is the current Chair of the Coeliac UK Health Advisory Council. Previous roles include chair of the British Society of Gastroenterology (BSG) Small Bowel and Nutrition Section (2006-2012), BSG Audit Committee (2010-2013), BSG Council Member (2016-19), President of the International Society for the Study of Coeliac Disease 2015-2019 (ISSCD) and Board Member of the European Society for study of Celiac Disease (ESsCD) from 2017-2020. The Sheffield Unit has recently been designated as the UK National Centre for Refractory Coeliac Disease (2019) and a World Endoscopy Organisation GI Centre of Excellence (2020).
Director of Research at Denver Nephrology Research
Dr Geoffrey Block is the Director of Research at Denver Nephrology Research, a department he founded in 1998 to provide translational research for patients with chronic kidney disease. His work focuses on mineral metabolism, cardiovascular disease (including anaemia management) and reno-protective therapy (anti-inflammatory). He has been the principal investigator on over 95 clinical trials spanning all phases of clinical research; has served on several international guideline committee workgroups, a steering committee member of several international clinical outcome clinical trials, and has been elected to the Executive Committee of KDIGO (Kidney Disease: Improving Global Outcome).
Head of Mucosal Immunology Laboratory at the Institute of Biochemistry and Cell Biology – Italian National Council of Research
Dr Carmen Gianfrani is an immunologist, Head of Mucosal Immunology Laboratory at the Institute of Biochemistry and Cell Biology – Italian National Council of Research (IBBC - CNR). Her scientific interest is mainly focused on the pathogenesis of gluten related disorders and immunotherapies to restore oral tolerance to gluten proteins in Celiac Disease patients. She has also contributed to develop biochemical strategies detoxifying wheat gluten, that are currently in clinical trials. Dr Gianfrani is section editor of Pediatric Research and coordinator of Science Outreach Program at IBP CNR.
Medical Affairs Director EU&ROWat Santhera Pharmaceuticals
Dr Pereira is the Medical Affairs Director EU&ROW at Santhera and prior to that was Medical Affairs Lead at Vifor UK. She has worked across multiple therapy areas including Rare Disease, Nephrology, Cardiology and Haematology. Before moving to Pharma in 2018 she was a Research Group Leader at the Department of Pathology, University of Cambridge. Her research focused on understanding the risk-benefit balance of oral iron in iron deficiency, the gut microbiome and enteric infections. She was a Principal Investigator with the MRC Unit The Gambia on a clinical trial investigating the safety and efficacy of oral iron supplements in young children. Dr Pereira contributed to invention of the patented technology behind IHAT.
Senior Associate Scientist at Fondazione Istituto Insubrico di Ricerca per la Vita
Linda Cavaletti is a biologist with long expertise in isolation and cultivation of strains for natural products discovery. Her professional carrer started in the Lepetit Research Center (then Biosearch Italia, then Vicuron Pharmaceuticals), where she could discover new microbial taxa, including previously uncultivated strains. Since 2008, she joined FIIRV focusing her activity on the generation of a FIIRV proprietary strain library. After diagnoses concerning family members, she developed a deep interest in celiac disease and its pathogenesis, culminating in a project for discovery of a new glutenase by acidophilic actinomycete strains. Since that time, she is leader of the Celiac Disease project in FIIRV, which led to discovery of E40, and its patenting in 2011. Since 2017, she collaborates with Nemysis for E40 development.
Nutritional deficiency research for healthier living
Head Office
Suite 4.01 Ormond Building
31-36 Ormond Quay Upper
Arran Quay
Dublin 7
D07 F6DC
Ireland
© Nemysis Ltd 2024 | Web design by Genetic Digital Privacy Policy | Cookie Policy